February 18, 2022 7:35am
A TGIF with an option expiration Friday as markets are closed Monday, President’s Day
Pre-open indications: 8 BUYs, 6 SELLs and 1 Pimp/Pump/Promote
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Earnings Reporting Dates: see below
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Only the facts … I ask questions and note the indications
Dow futures are DOWN -0.11% (-37 points), S&P futures are DOWN -0.05% (-2 points) and NASDAQ futures are UP +0.01% (+2 points)
Stock futures are flipping to the dark side (lower) in early premarket trad after the sell-offs on Friday
European markets were muted, with global sentiment hanging in the balance
Asia-Pacific markets mostly slid overnight about the Russia-Ukraine tensions
Henry’omics:
Indexes suffered a steep sell-off on Thursday, with the Dow falling more than 600 points for its biggest daily drop since end of November, the S&P 500 dropped more than 2% to break a two-day winning streak, as the Nasdaq declined 2.9%.
Side by side with the cell and gene therapy sector being shoved-down the chute
If you didn’t remember what happen at Thursday’s close, you won’t be prepared for today’s session,
RegMed Investors’ (RMi) closing bell: “yet another cell and gene therapy sector sell-off. Cheaper and cheaper equities set the stage for an algorithmic rebound” … https://www.regmedinvestors.com/articles/12307
Ebb and flow –
- February stats: 8 negative and 5 positive closes
- January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628
The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306
Companies in my headlights – It’s your decision; I provide ideas and context:
Pre-open share pricing ... indications:
BUY:
Adverum Biotechnologies (ADVM) +$0.03 or +2.19%
CRISPR Therapeutics (CRSP) +$1.19 or +2.03%
Fate Therapeutics (FATE) +$1.29 or +3.83%
Global Blood Therapeutics (GBT) +$1.59 or +4.82%
Ultragenyx (RARE) +$0.27 or +0.40%
Sage Therapeutics (SAGE) +$1.32 or +3.93%
Sangamo Therapeutics (SGMO) +$0.24 or +4.20%
Verastem (VSTM) +$0.03 or +2.40%
SELL:
BioLife Solutions (BLFS) -$0.56 or -2.37%,
bluebird bio (BLUE) -$0.08 or -1.30%,
Cellectis SA (CLLS) -$0.06 or -1.12%
Mesoblast (MESO) -$0.07 or -1.72%
Pluristem (PSTI) -$0.05 or -2.87%
ReNeuron (RENE.L) -$0.85 or -2.211%
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed UP +$0.06 with 700 shares traded after Wednesday -$0.06 (had been -$0.98) with 420 shares traded, Tuesday’s flat with 200 shares traded and Monday’s flat with 1,899 shares traded
- WHO is BUYING these shares of a company with a 2-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
- Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: extended losses are also being expressed through option expiration.
Next week is “heavy” earnings reporting
But I see opportunity post next week’s reporting … I do like being early; let’s see who dips, slip and possibly gains a little attitude early in Friday’s trading day (option covering) before entering the recently zombie cell and gene sector
Reiteration, I continue my skittishness regarding earnings’ reporting and the volatility in trading that usually precedes and follows releases.
Investors have to recognize what kind of market we are STILL in – VOLATILE with LOW VOLUME. Which gives us reasons to be cautious.
Earnings’ reporting:
- AxoGen AXGN) – Tuesday, 2/22
- Global Blood Therapeutics (GBT) – Wednesday, 2/23
- Sage Therapeutics (SAGE), Thursday, 2/24
- Ionis Pharmaceuticals (IONS) - Thursday, 2/24
- Sangamo Therapeutics (SGMO) - Thursday, 2/24
- Editas Medicine (EDIT) - Thursday, 2/24
- Fate therapeutics, Monday, 2/28
- Athersys (ATHX), Tuesday, 3/15
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
I am NOT changing my position, “Brace for more choppiness as we move further into the month and the beginning of Q1/22 waiting for Q4 and FY21 numbers”.
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.
